[HTML] springer.comFull View

[HTML][HTML] The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease

Y Lin, TH Wang, ML Tsai, VCC Wu, CJ Tseng… - Cardiovascular …, 2023 - Springer
Background To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …
被引用次数：7 相关文章

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease

Y Lin, W Te-Hsiung, ML Tsai, VCC Wu… - Cardiovascular …, 2023 - search.proquest.com
Background To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease.

Y Lin, TH Wang, ML Tsai, VCC Wu… - Cardiovascular …, 2023 - search.ebscohost.com
Background: To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …
[HTML] biomedcentral.com

[HTML][HTML] The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease

Y Lin, TH Wang, ML Tsai, VCC Wu… - Cardiovascular …, 2023 - cardiab.biomedcentral.com
To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs) have
cardiovascular and renal protective effects in patients with advanced diabetic kidney …
[HTML] nih.gov

[HTML][HTML] The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease

Y Lin, TH Wang, ML Tsai, VCC Wu… - Cardiovascular …, 2023 - ncbi.nlm.nih.gov
Background To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease

Y Lin, TH Wang, ML Tsai, VCC Wu… - Cardiovascular …, 2023 - pubmed.ncbi.nlm.nih.gov
Background To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease.

Y Lin, TH Wang, ML Tsai, VC Wu, CJ Tseng… - Cardiovascular …, 2023 - europepmc.org
Background To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease

Y Lin, TH Wang, ML Tsai, VCC Wu, CJ Tseng, MS Lin… - 2023 - researchsquare.com
Background To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease.

Y Lin, TH Wang, ML Tsai, VC Wu, CJ Tseng… - Cardiovascular …, 2023 - europepmc.org
Background To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs)
have cardiovascular and renal protective effects in patients with advanced diabetic kidney …